Meridian Clinical Research, a leading investigative research network, has finished enrolling participants into Moderna’s Phase 3 clinical trial for mRNA-1273, its COVID-19 vaccine candidate.
Today, Moderna reached its goal of 30,000 participants for the Phase 3 clinical trial. Meridian conducted the study at eight of its sites, and enrolled more than 2,750 participants into the trial.
“We’re beyond grateful to every COVID-19 vaccine trial participant,” said Nicole Osborn, Founder and CEO of Meridian. “Many who have joined COVID-19 vaccine studies at Meridian are new to clinical research, and they joined to help end this pandemic. Without participants, it wouldn’t be possible to research and develop new vaccines — participants are, and will always be, the heroes in our shared journey to improve human health and wellbeing.”
Paul Bradley, MD, a Principal Investigator at Meridian, was the first investigator to dose a Phase 3 COVID-19 vaccine study patient in the US as part of Moderna’s clinical trial. Dr. Bradley led study conduct at Meridian’s internal medicine site in Savannah, GA, and has been outspoken about the importance of diversity and inclusion in COVID-19 vaccine clinical trials.
Last week, officials from the U.S. Department of Health and Human Services (HHS) visited with Meridian leaders. The group toured Meridian’s internal medicine site in Savannah, then held a roundtable discussion about Meridian’s patient recruitment efforts and the research the company has conducted for COVID-19 vaccine clinical trials nationwide.
Meridian is still conducting COVID-19 vaccine clinical trials at 8 of its 23 sites. Earlier this month, the company won the 2020 Vaccine Industry Excellence (ViE) award for Best Clinical Trial Site, along with the ViE award for Best Clinical Trial Network as the largest member of Platinum Research Network.
Meridian Clinical Research